An approval of Lilly's pill, along with its current strength in the weight loss market, could equal revenue growth well into ...

The about-$1 billion deal could come imminently.

Here's how we employ swing trading strategies of selling into strength, selling into weakness and cutting a loss quickly.

Aktis Oncology Inc., a clinical-stage biotechnology company that counts Eli Lilly & Co. among its backers, raised $317.7 ...

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Schrödinger (SDGR) stock and Revvity (RVTY stock are in focus as firms join Eli Lilly (LLY) to integrate their software with ...

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Eli Lilly has doubled its investment in its new Concord manufacturing facility from $1 billion to $2 billion since construction began in 2022, the company confirmed. The pharmaceutical giant hosted a ...

(Editor’s note: This story was written before Eli Manning was not included in the Pro Football Hall of Fame class of 2025.) Two guys are sitting in a bar. They could be talking about who the Giants’ ...